Ioxilan
Ioxilan|
|
| Systematic (IUPAC) name |
|---|
|
1-N-(2,3-dihydroxypropyl)-5-[N-(2,3-dihydroxypropyl)acetamido]-3-N-(2-hydroxyethyl)-2,4,6-triiodobenzene-1,3-dicarboxamide |
| Clinical data |
|---|
| AHFS/Drugs.com |
International Drug Names |
|---|
|
- US: B (No risk in non-human studies)
-
|
|---|
|
|
|---|
|
intravenously |
|---|
| Pharmacokinetic data |
|---|
| Bioavailability |
N/A |
|---|
| Protein binding |
negligible |
|---|
| Half-life |
2 hours |
|---|
| Excretion |
Mostly renal |
|---|
| Identifiers |
|---|
|
107793-72-6  N |
|---|
|
V08AB12 |
|---|
| PubChem |
CID 3743 |
|---|
| ChemSpider |
3612  Y |
|---|
| UNII |
A4YJ7J11TG Y |
|---|
| KEGG |
D02161 Y |
|---|
| ChEMBL |
CHEMBL1201075 N |
|---|
| Chemical data |
|---|
| Formula |
C18H24I3N3O8 |
|---|
|
791.112 |
|---|
SMILES
- O=C(N(c1c(I)c(c(I)c(c1I)C(=O)NCCO)C(=O)NCC(O)CO)CC(O)CO)C
|
InChI=1S/C18H24I3N3O8/c1-8(28)24(5-10(30)7-27)16-14(20)11(17(31)22-2-3-25)13(19)12(15(16)21)18(32)23-4-9(29)6-26/h9-10,25-27,29-30H,2-7H2,1H3,(H,22,31)(H,23,32)
Y
Key:UUMLTINZBQPNGF-UHFFFAOYSA-N
Y
|
| N (what is this?) (verify) |
|---|
Ioxilan is a diagnostic contrast agent. It is injected intravenously before taking X-ray images to increase arterial contrast in the final image. It is marketed under the trade name Oxilan by Guerbet, L.L.C.
|
|---|
| | X-ray and CT | Iodinated,
Water soluble | Nephrotropic,
high osmolar | |
|---|
| Nephrotropic,
low osmolar | |
|---|
| Hepatotropic | |
|---|
|
|---|
| Iodinated,
Water insoluble | |
|---|
| Non-iodinated | |
|---|
|
|---|
| | MRI | Paramagnetic |
Other: Ferric ammonium citrate
|
|---|
| | |
|---|
| Other | |
|---|
|
|---|
| | Ultrasound | |
|---|
| |
|
